CRISPR Therapeutics Strategy, SWOT and Corporate Finance Report [Report Updated: 20062018] Prices from USD $175

19:07 EDT 31 Aug 2018 | BioPortfolio Reports

CRISPR Therapeutics Strategy, SWOT and Corporate Finance Report


CRISPR Therapeutics Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.

Key Highlights

CRISPR Therapeutics AG CRISPR is a gene editing company created to translate CRISPRCas9, a breakthrough geneediting technology, into transformative medicines for serious human diseases. The company classifies its business into single operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genomeediting technology. Through its CRISPR/Cas9 geneediting technology, the company allows selective deletion, modification or correction of a disease causing abnormality in a specific DNA segment. It primarily operates in Switzerland, the UK, and the US. The company is headquartered in Basel, Switzerland.


Detailed information on CRISPR Therapeutics required for business and competitor intelligence needs

A study of the major internal and external factors affecting CRISPR Therapeutics in the form of a SWOT analysis

An indepth view of the business model of CRISPR Therapeutics including a breakdown and examination of key business segments

Intelligence on CRISPR Therapeutics's mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

News about CRISPR Therapeutics, such as business expansion, restructuring, and contract wins

Large number of easytograsp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of CRISPR Therapeutics and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess CRISPR Therapeutics as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on CRISPR Therapeutics's business structure, strategy and prospects.

Original Article: CRISPR Therapeutics Strategy, SWOT and Corporate Finance Report [Report Updated: 20062018] Prices from USD $175


More From BioPortfolio on "CRISPR Therapeutics Strategy, SWOT and Corporate Finance Report [Report Updated: 20062018] Prices from USD $175"

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...